Anbio Biotechnology (NNNN) Total Current Liabilities (2023 - 2025)

Anbio Biotechnology has reported Total Current Liabilities over the past 3 years, most recently at $87836.0 for Q4 2025.

  • Quarterly results put Total Current Liabilities at $87836.0 for Q4 2025, down 94.92% from a year ago — trailing twelve months through Dec 2025 was $87836.0 (down 94.92% YoY), and the annual figure for FY2025 was $87836.0, down 94.92%.
  • Total Current Liabilities for Q4 2025 was $87836.0 at Anbio Biotechnology, down from $1.7 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for NNNN hit a ceiling of $1.7 million in Q4 2024 and a floor of $87836.0 in Q4 2025.
  • Median Total Current Liabilities over the past 3 years was $993060.0 (2023), compared with a mean of $937043.3.
  • Biggest five-year swings in Total Current Liabilities: soared 74.23% in 2024 and later plummeted 94.92% in 2025.
  • Anbio Biotechnology's Total Current Liabilities stood at $993060.0 in 2023, then soared by 74.23% to $1.7 million in 2024, then plummeted by 94.92% to $87836.0 in 2025.
  • The last three reported values for Total Current Liabilities were $87836.0 (Q4 2025), $1.7 million (Q4 2024), and $993060.0 (Q4 2023) per Business Quant data.